INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE – ARGX

NEW YORK CITY, NY / ACCESS Newswire / July 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ:ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors […]

Class Action Lawsuit Filed Against Krispy Kreme, Inc. (DNUT) – Recover Losses – Contact Levi & Korsinsky Before July 15, 2025

NEW YORK, NY / ACCESS Newswire / July 1, 2025 / If you suffered a loss on your Krispy Kreme, Inc. (NASDAQ:DNUT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/krispy-kreme-inc-lawsuit-submission-form?prid=155167&wire=1&utm_campaign=9 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or

Plains All American’s 2024 Schedule K-3 Now Available

Plains All American's 2024 Schedule K-3 Now Available GlobeNewswire July 01, 2025 HOUSTON, July 01, 2025 (GLOBE NEWSWIRE) — Plains All American Pipeline, L.P. (Nasdaq: PAA) (the “Partnership”) announced today that its 2024 Schedule K-3 reflecting items of international tax relevance is available online. Unitholders requiring this information may access their Schedules K-3 at www.taxpackagesupport.com/plainsallamerican.

AES Announces Second Quarter 2025 Financial Review Conference Call to be Held on Friday, August 1, 2025 at 10:00 a.m. ET

The AES Corporation (NYSE: AES) will host a conference call on Friday, August 1, 2025 at 10:00 a.m. Eastern Time (ET) to review its second quarter 2025 financial results. https://mma.prnewswire.com/media/1321840/AES_Logo.jpg The call will include prepared remarks and a question and answer session. It will be open to the media and the public in a listen-only

Highland Opportunities and Income Fund Announces the Regular Monthly Distribution

The Highland Opportunities and Income Fund (NYSE: HFRO) (“HFRO” or the “Fund”) today announced its regular monthly distribution on its common stock of$0.0385 per share. The distribution will be payable on July 31, 2025, to shareholders of record at the close of business July 24, 2025. The Fund is a closed-end fund that seeks to

Highland Global Allocation Fund Declares Monthly Distributions of $0.088 Per Share

Highland Global Allocation Fund (NYSE:HGLB) (“the “Fund”) today announced the declaration of monthly distributions of $0.088 per share, payable on the dates noted below. Under the Fund's level distribution policy, the annual distribution rate has been reset to an amount equal to 8.5% of the average of the Fund's net asset value (“NAV”) per share,

American Bitcoin and Gryphon Digital Mining Advance Toward Public Listing of American Bitcoin with Filing of Amended Registration Statement on Form S-4

American Bitcoin expected to trade on Nasdaq under the ticker symbol “ABTC” American Bitcoin Corp. (“American Bitcoin” or the “Company”), a Bitcoin accumulation platform focused on building America's Bitcoin infrastructure backbone, and Gryphon Digital Mining, Inc. (Nasdaq: GRYP) (“Gryphon”), an innovative venture in the Bitcoin mining space, today announced the filing of an amended registration

Boqii Holding Limited Announces Update on Substitution Listing and 1-for-160 Reverse Split

AsBoqii Holding Limited (“Boqii” or the “Company”) (NYSE American:BQ) previously announced, the Company plans to cease the listing of its American Depositary Shares (the “ADSs”) on the NYSE American LLC (“AMEX”) and list its Class A ordinary shares of a par value of US$0.16 each on a post-reverse stock split basis for trading on AMEX

Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

(NASDAQ:CDTX), SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company applying its proprietary Cloudbreak(R) platform to develop drug-Fc conjugate (DFC) therapeutics, today announced that the Compensation and Human Capital Committee of its Board of Directors (Compensation Committee) granted non-qualified stock option awards and restricted stock units (RSUs) for

Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

(NasdaqGM:ZNTL), SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) — Zentalis(R) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 inhibitor for patients with ovarian cancer and other tumor types, today announced that on July 1, 2025, the Compensation Committee of Zentalis' Board of Directors granted non-qualified stock options to

Scroll to Top